Translational Haematology
Our Translational Hematology group was created with the aim of generating knowledge in the field of hematology and collaborating with other groups for the implementation of projects. Our activity is based on a broad portfolio of clinical trials, basic research projects and registry studies. The area of knowledge in which we focus is the study of the immune system and its relationship with oncohematological diseases and their infectious complications, cell therapy, study of the adverse effects of drugs and optimization in obtaining and using blood components in Transfusion Therapy.
Search for publications
Only original articles, editorials, guidelines.
-
Velasco-Rodríguez D, Martínez-Alfonzo I, Velasco-Valdazo AE, Domingo-González A, Revilla N, Mahíllo-Fernández I, Askari E, Blanchard MJ, Vidal Laso R, Fernández-Cuezva L, Castro-Quismondo N, Prieto E, Serrano-López J, Rosado B, Naya D, Martín-Herrero S, Menéndez M, Yuste M, Sánchez-Prieto I, Jiménez-Martín A, Bueno MÁ, de la Plaza R, Martínez-López J, Calvo-Villas JM, López-Jiménez J, Llamas-Sillero P.
Significant attenuation of fully automated thrombin generation in newly diagnosed multiple myeloma patients after induction therapy
JOURNAL OF THROMBOSIS AND THROMBOLYSIS . 58(3): 467-480.
-
Villarrubia J, Morales M, Ceberio L, Vitoria I, Bellusci M, Quiñones I, Peña L, Ruiz de Valbuena M, O'Callaghan M.
Ecological study to estimate the prevalence of patients with acid sphingomyelinase deficiency in Spain. PREVASMD study.
Revista clinica espanola . 225(2): 70-77.
-
Pascual-Izquierdo C, Llacer-Ferrandis MJ, de-la-Iglesia A, Monsalvo-Saornil S, Menor-Gómez M, Gil-Fernández JJ, Chica-Gullon E, Álvarez-Román MT, Perez-Segura G, Zafra D, Ortuzar-Pasalodos A, González-Gascón-Y-Marín IT, Moreno G, Arquero-Portero T, Moreno-Carbonell M, Revilla N.
Avatrombopag in adults with immune thrombocytopenia: A multicentre real-life observational study in Madrid, Spain (AVAMAD study)
BRITISH JOURNAL OF HAEMATOLOGY . 206(2): 652-656. Number of citations: 2
-
Valtis YK, Devlin SM, Shouval R, Rejeski K, Corona M, Luna De Abia A, Rivas-Delgado A, Luttwak E, Cassanello G, Landego I Dr, Schöder H, Bedmutha A, Boardman AP, Shah GL, Scordo M, Perales MA, Salles GA, Palomba ML, Shah UA, Park JH.
Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes
Blood Advances . 9(1): 151-161. Number of citations: 9
-
Melica G, Luna de Abia A, Shah GL, Devlin S, Corona M, Fein J, Dahi PB, Giralt SA, Lin RJ, Palomba ML, Parascondola A, Park J, Salles G, Saldia A, Scordo M, Shouval R, Perales MA, Seo SK.
Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort
Transplantation And Cellular Therapy . 31(1): 36-44. Number of citations: 6
-
Rodríguez-Arbolí E, Rodríguez-Veiga R, Soria-Saldise E, Bergua JM, Caballero-Velázquez T, Arnán M, Vives S, Serrano J, Bernal T, Martínez-Sánchez P, Tormo M, Rodríguez-Medina C, Herrera-Puente P, Lavilla-Rubira E, Boluda B, Acuña-Cruz E, Cano I, Cáceres S, Ballesteros J, Falantes J, Martínez-Cuadrón D, Pérez-Simón JA, Montesinos P.
A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.
CANCER . 131(1): . Number of citations: 2
-
Fernández de Larrea C, Loscertales J, Cabañas V, Freiria C, Blanchard MJ, Askari E, Lorenzo Pérez M, Abril L, López Pardo J, Pinzón S, Díaz Gálvez J, Amer N, Ramírez Páyer Á, García Sánchez R, Alcalá MM, Capote FJ, Moreno D, Bolumburu C, Rubio-Azpeitia E, García Sanz R.
Observational retrospective study of the treatment of Waldenstrom's macroglobulinemia with ibrutinib in routine clinical practice in Spain.
Therapeutic Advances in Hematology . 16: .
-
Escamilla-Gómez V, García Gutiérrez V, Alcalde-Mellado P, Astibia-Mahillo B, Chinea-Rodriguez A, López-Corral L, Acera-Gómez M, Torres Ochando MK, Borrero Borrego A, González Pinedo L, Zudaire Ripa T, González Vicent M, Benzaquén A, Izquierdo Garcia I, Asensi Cantó P, Montoro J, Martín-Domínguez FM, Orti G, Valcárcel D, Benitez-Carabante MI, Diaz-de-Heredia C, Cañamero E, Ferrá C, García-Cadenas I, Redondo S, Sisinni L, Perez-Martínez A, Mussetti A, Garcia-Mañó L, Palomo-Moraleda MDP, González-Sierra PA, Jurado M, Perez-Simon JA.
Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC.
BONE MARROW TRANSPLANTATION . : . Number of citations: 4
-
Puig N, Agullo Roca C, Sanfeliciano TC, Cedena MT, Martínez-López J, Oriol A, Blanchard MJ, Ríos-Tamayo R, Iñigo Rodríguez B, Sureda A, Lakhwani S, de la Rubia Comos J, Gonzalez-Calle V, Cabañas V, Palomera L, Moraleda JMM, Bargay J, Castro S, Rosiñol L, Bladé J, San-Miguel JF, Lahuerta JJ, Paiva B, Mateos MV.
Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma.
BLOOD . 144(23): 2432-2438. Number of citations: 14
-
Puig N, Agulló C, Contreras T, Pérez JJ, Aires I, Calasanz MJ, García-Sanz R, Castro S, Martínez-López J, Rodríguez-Otero P, González-Calle V, González MS, Oriol A, Gutiérrez NC, Ríos-Tamayo R, Rosiñol L, Álvarez MÁ, Bargay J, González-Rodríguez AP, Alegre A, Escalante F, Iñigo MB, De la Rubia J, Teruel AI, De Arriba F, Palomera L, Hernández MT, López-Jiménez J, Reinoso M, García-Mateo A, Ocio EM, Bladé J, Lahuerta JJ, Cedena MT, Paiva B, Miguel JFS, Mateos MV.
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial.
Haematologica . 109(12): 4056-4066. Number of citations: 6
-
Santaliestra M, Garrote M, Noya MS, Pérez-Encinas M, Senín A, Pérez-López R, Ferrer-Marín F, Carreño-Tarragona G, Caballero G, Magro E, Vélez P, Cortés Vázquez MÁ, Moretó A, Angona A, Pastor-Galán I, Guerra JM, García Hernández C, Mata MI, Stuckey R, Gómez-Casares MT, Fox L, Cuevas B, García-Gutiérrez V, Triguero A, Arellano-Rodrigo E, Hernández-Boluda JC, Alvarez-Larrán A.
Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia.
Leukemia . 38(12): 2636-2643.
-
Quinonero, Isabel Rodenas, Marco-Ayala, Javier, Chen-Liang, Tzu-Hua, de la Cruz-vicente, Fatima, Baumann, Tycho, Navarro, Jose-Tomas, Garcia-Sancho, Alejandro Martin, Martin-Santos, Taida, Lopez-Jimenez, Javier, Andreu, Rafael, Parra, Ester, Usas, Andrea, Alonso, David, Fernandez-Gonzalez, Marta, Rumschisky, Pablo Palomo, Frutos, Laura, Navarro, Jose Luis, Alvarez-Perez, Rosa Maria, Sarandeses, Pilar, Cortes, Montserrat, Tamayo, Pilar, Una, Jon, Martinez-Lorca, Alberto, Ruiz, Cristina, Lozano, Maria Luisa, Ortuno, Francisco Jose.
The Value of Bone Marrow Assessment by FDG PET/CT, Biopsy and Aspirate in the Upfront Evaluation of Mantle Cell Lymphoma: A Nationwide Cohort Study
Cancers . 16(24): . Number of citations: 3
-
Hammoud, Miloud, Dominguez-Ruiz, Maria, Assiri, Imane, Rodrigues, Daniel, Aboussair, Nisrine, Lanza, Val F., Villarrubia, Jesus, Colon, Cristobal, Fdil, Naima, del Castillo, Francisco J..
Metachromatic Leukodystrophy in Morocco: Identification of Causative Variants by Next-Generation Sequencing (NGS)
GENES . 15(12): . Number of citations: 2
-
Vives S, Quintela D, Morgades M, Cano-Ferri I, Serrano A, Acuña-Cruz E, Cervera M, Díaz-Beyá M, Vidriales B, Raposo-Puglia JÁ, Arnan M, Garrido A, Balerdi A, Cabello AI, Herrera-Puente P, Serrano J, Coll R, Tormo M, López-Marín J, García-Ávila S, Casado MS, Padilla I, Rodríguez-Macías G, Calbacho M, Puchol A, Hernández A, Torres M, Costilla L, Colorado MM, Martínez-Cuadrón D, Esteve J, Montesinos P.
Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups.
Cancers . 16(23): . Number of citations: 3
-
Garcia-Gutierrez V, Huang F, Ashaye A, Dalal M, Laliman-Khara V, Breccia M, Rutherford M, Moradian H, Patos P, Jabbour EJ.
Ponatinib vs. asciminib in post-second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison.
Frontiers in Oncology . 14: 1455378-1455378. Number of citations: 4
-
Pastor-Galán I, Pereira A, Arellano-Rodrigo E, Martín I, Mosquera-Orgueira A, Gómez-Casares MT, Hernández-Sánchez A, Ferrer-Marín F, Mora E, Velez P, Ayala R, Angona A, de Las Heras N, Magro E, Mata-Vázquez MI, Fox ML, González de Villambrosía S, Ramírez MJ, García A, García-Gutiérrez V, Cáceres A, Durán MA, Senín MA, Raya JM, González JA, Cuevas B, Xicoy B, Garrote M, Ferrer B, Pérez-Encinas M, Hernández-Rivas JM, Bellosillo B, Álvarez-Larrán A, Hernández-Boluda JC.
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.
Leukemia . 38(11): 2483-2486.
-
Pérez-Lamas L, Díaz AS, Casterá EM, Soto MH, Coll AP, De Las Heras N, Cortes M, Tenza PV, Pacho MS, Magan AS, Angona A, Cervero C, de Paz R, Cuenca AS, Santaliestra M, Marín JL, Casado LF, García-Gutiérrez V.
Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib.
ANNALS OF HEMATOLOGY . 103(11): 4537-4544. Number of citations: 2
-
Rodríguez-Mora S, Sánchez-Menéndez C, Bautista-Carrascosa G, Mateos E, Moreno-Serna L, Megías D, Cantón J, García-Gutiérrez V, Murciano-Antón MA, Cervero M, Spivak A, Planelles V, Coiras M.
Dasatinib interferes with HIV-1 proviral integration and the inflammatory potential of monocyte-derived macrophages from people with HIV.
BIOCHEMICAL PHARMACOLOGY . 229: 116512-116512. Number of citations: 3